

Fidelity Global Equities

Quarterly Investment Option Update

31 December 2018

Aim and Strategy

To achieve returns in excess of the MSCI All Country World (ex-Australia) (ex-Tobacco) Index over the suggested minimum investment time period of five to seven years. The strategy takes a go-anywhere approach – it isw managed with broad geographic and sector parameters to allow the portfolio manager to build a portfolio of the best opportunities uncovered by the investment manager's global research in core international investment. Fidelity believes that markets are semi-efficient and share prices don't always reflect inherent value. Through in-house, bottom-up company research, Fidelity aims to uncover the opportunities that it believes offer the greatest scope for outperformance. Based on this research approach, Fidelity seeks out shares that it believes are undervalued and likely to generate growth. The companies selected for the portfolio demonstrate good management, strong competitive advantages and enjoy favourable industry dynamics. The option's exposure to international assets will not be hedged back to Australian dollars.

Investment Option Performance

To view the latest investment performances for each product please visit amp.com.au

Investment Option Overview

Investment category	Global Shares	
Suggested investment timeframe	ment timeframe 5 to 7 years	
Relative risk rating	6 / High	
Investment style	Core	

Asset Allocation	Benchmark (%)	Actual (%)
Global Shares	90-100	96.32
Cash & ONA	0-10	3.68

Regional Allocation	%
NORTH AMERICA	51.58
EUROPE EX UK	20.72
EMERGING MARKETS	9.25
JAPAN	7.10
UK	6.66
PACIFIC EX JAPAN	1.02
MIDDLE EAST	0.00
CASH & ONA	3.68

Sector Allocation	%
FINANCIALS	19.07
INFORMATION TECHNOLOGY	14.80
HEALTH CARE	12.81
COMMUNICATION SERVICES	10.15
ENERGY	8.55
INDUSTRIALS	7.55
CONSUMER DISCRETIONARY	7.37
CONSUMER STAPLES	6.06
MATERIALS	5.11
REAL ESTATE	3.65
UTILITIES	1.20
CASH & ONA	3.68

Top Holdings	%
MICROSOFT CORP	2.41
MERCK & CO INC NEW	2.24
ALPHABET INC	2.07
ROCHE HOLDING LTD	1.80
ROYAL DUTCH SHELL PLC	1.70
VISA INC	1.60
JPMORGAN CHASE & CO	1.59
ORACLE CORP	1.58
COCA COLA CO	1.57
WELLS FARGO & CO NEW	1.51

Investment Option Commentary

Conviction health care positions added value

Merck & Co is witnessing solid business momentum on the back of a strong competitive position in first-line lung cancer treatment and a robust pipeline. Roche Holdings rose as it received early approval for its influenza medicine Xofluza. The company has a positive late stage pipeline. Conversely, Sysmex declined due to weak quarterly results and a downward revision to its full-year guidance.

Financials rose on favourable regulatory landscape

Regulatory approvals for the acquisition of NEX Group and robust earnings boosted shares in CME Group. Kotak Mahindra Bank and ICICI Lombard General Insurance gained following the relaxation of liquidity norms by the Indian central bank and hopes of a more favourable regulatory environment from the new central bank governor.

Market Commentary

Concerns about a possible global economic slowdown, subdued earnings releases from US information technology majors and the US Federal Reserve's interest rate hikes weighed on sentiment. Continued Brexit-related uncertainties and ongoing US-China trade frictions further worried investors. While key holdings in financials and health care sectors added value, certain communication services and energy positions hurt returns.

Outlook

Going into 2019, Fidelity remains cautious on the outlook for global equities in view of risks in the current late-cycle environment. Global economic slowdown concerns, tightening US monetary conditions, global trade frictions, Brexit-related uncertainty and softening corporate earnings present headwinds to the global economy. However, a late cycle is still positive for risk assets, and high market volatility can create interesting dislocations and throw up interesting buying opportunities to add value.

Availability

Product name	APIR
AMP Flexible Lifetime Super	AMP1291AU
AMP Flexible Super - Retirement account	AMP1342AU
AMP Flexible Super - Super account	AMP1471AU
CustomSuper	AMP1291AU
Flexible Lifetime - Allocated Pension	AMP1298AU
Flexible Lifetime - Term Pension	AMP1638AU
Flexible Lifetime Investment	AMP0846AU
Flexible Lifetime Investment (Series 2)	AMP1432AU
SignatureSuper	AMP1305AU
SignatureSuper Allocated Pension	AMP1312AU

Contact Details

Web: www.amp.com.au Email: askamp@amp.com.au

Phone: 131 267 (Mon. to Fri. 8:30am to 7:00pm AEST)

What you need to know

This publication has been prepared by AMP Life Limited ABN 84 079 300 379, AFSL No. 233671 (AMP Life). The information contained in this publication has been derived from sources believe to accurate and reliable as at the date of this document. Information provided in this investment option update are views of the underlying Investment Manager only and not necessarily the views of the AMP Group. No representation is given in relation to the accuracy or completeness of any statement contained in it. Whilst care has been taken in the preparation of this publication, to the extent permitted by law, no liability is accepted for any loss or damage as a result of reliance on this information. AMP Life is part of the AMP Group. In providing the general advice, AMP Life and AMP Group receives fees and charges and their employees and directors receive salaries, bonuses and other benefits.

The information in this document is of a general nature only and does not take into account your financial situation, objectives and needs. Before you make any investment decision based on the information contained in this document you should consider how it applies to your personal objectives, financial situation and needs, or speak to a financial planner.

The investment option referred to in this publication is available through products issued by AMP Superannuation Limited ABN 31 008 414 104, AFSL No. 233060 (ASL) and/or AMP Life. Before deciding to invest or make a decision about the investment options, you should read the current Product Disclosure Statement for the relevant product, available from ASL, AMP Life or your financial planner.

Any references to the "Fund", strategies, asset allocations or exposures are references to the underlying managed fund that the investment option either directly or indirectly invests in (underlying fund). The investment option's aim and strategy mirrors the objective and investment approach of the underlying fund. An investment in the investment option is not a direct investment in the underlying fund.

Neither AMP Life, ASL, any other company in the AMP Group nor underlying fund manager guarantees the repayment of capital or the performance of any product or particular rate of return referred to in this document. Past performance is not a reliable indicator of future performance.

